CLINICAL PHARMACOLOGY OF METABOLISM-ACTIVATING AND CORRECTING DRUGS
Keywords:
Metabolic correction, mitochondrial function, metabolic syndrome, actoprotectors.Abstract
This article explores the clinical pharmacology of metabolism-activating
and correcting drugs, a heterogeneous group of agents designed to restore or optimize
metabolic processes in pathological conditions. It provides an overview of drug classes,
mechanisms of action, pharmacokinetics, clinical applications, and safety considerations.
Special attention is given to the role of these agents in mitochondrial dysfunction, ischemia,
metabolic syndrome, and neurodegeneration. The article highlights current evidence and
emerging therapeutic strategies in both acute and chronic disease management.
References
Tarnopolsky, M. A. Metabolic myopathies. – Continuum (Minneap Minn). – 2016. –
Vol. 22, №6. – P. 1829–1851.
Dunning, A. L., et al. Coenzyme Q10 supplementation in heart failure: a meta-analysis. –
Clin Nutr. – 2019. – Vol. 38, №1. – P. 203–211.
Malaguarnera, M. Carnitine derivatives: clinical usefulness. – Curr Opin Gastroenterol. –
– Vol. 28, №2. – P. 166–176.
Liepinsh, E., et al. Mildronate treatment modifies lipid metabolism and reduces
inflammation markers in patients with type 2 diabetes mellitus. – J Clin Pharmacol. –
– Vol. 55, №3. – P. 327–335.
Ziegler, D., et al. Efficacy and safety of alpha-lipoic acid in diabetic neuropathy:
systematic review and meta-analysis. – Diabetes Care. – 2004. – Vol. 27, №8. – P. 1910
